EHA24: How I Treat Relapsed/Refractory Multiple Myeloma in Early Lines
Fredrik Schjesvold, Head of Oslo Myeloma Center, discusses his upcoming talk at EHA 2024 in Madrid about selecting second-line treatments for myeloma after the first relapse. He emphasizes considering overall survival and progression-free survival data, changing the mechanism of action, and the potential future impact of new drug combinations on treatment choices.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in